graph digitizer software package version 2.25 (GetData Pty Ltd)
90
Structured Review
GetData Pty Ltd
graph digitizer software package version 2.25
Graph Digitizer Software Package Version 2.25, supplied by GetData Pty Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/graph+digitizer+software+package+version+2%2E25/graph+digitizer/pmc12004809-134-2-8
Average 90 stars, based on 1 article reviews
Graph Digitizer Software Package Version 2.25, supplied by GetData Pty Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/graph+digitizer+software+package+version+2%2E25/graph+digitizer/pmc12004809-134-2-8
Average 90 stars, based on 1 article reviews
graph digitizer software package version 2.25 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Software:Article Title: Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. Article Snippet: Background and Objectives In first-line treatment of advanced renal cell carcinoma (aRCC), the KEYNOTE-426 study demonstrated a significant progression-free survival and overall survival for pembrolizumab plus axitinib in comparison with sunitinib.. The objective of the current study was to evaluate the cost effectiveness of pembrolizumab plus axitinib versus sunitinib for previously untreated patients with aRCC in China.. Methods A Markov model was used to estimate the costs and health outcomes of treatment of aRCC with sunitinib or pembrolizumab plus axitinib. Article Title: Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China Article Snippet: .. Due to the imbalance of economic development among different regions in china, we 153 selected $30,363/QALY as the willingness-to-pay (WTP) threshold value for general regions and 154 $70,353/QALY for affluent regions.25 155 2.2 Model survival and progression risk estimates 156 The clinical effectiveness data associated with ramucirumab plus erlotinib and placebo plus erlotinib 157 were available from the phase III RELAY trial, at the updated data cutoff (February 1, 2018).22 158 GetData Article Title: Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma Article Snippet: .. The GetData Article Title: Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis Article Snippet: .. GetData Article Title: First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma Article Snippet: .. 5 GetData Article Title: Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Article Snippet: Background Nivolumab plus standard chemotherapy has significant clinical benefits for unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC).. However, nivolumab is expensive, necessitating a cost-effectiveness evaluation.. Aim This study aimed to evaluate the cost-effectiveness of nivolumab plus standard chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic GC/GEJC/EAC from the Chinese healthcare system perspective. Generated:Article Title: Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. Article Snippet: Background and Objectives In first-line treatment of advanced renal cell carcinoma (aRCC), the KEYNOTE-426 study demonstrated a significant progression-free survival and overall survival for pembrolizumab plus axitinib in comparison with sunitinib.. The objective of the current study was to evaluate the cost effectiveness of pembrolizumab plus axitinib versus sunitinib for previously untreated patients with aRCC in China.. Methods A Markov model was used to estimate the costs and health outcomes of treatment of aRCC with sunitinib or pembrolizumab plus axitinib. Derivative Assay:Article Title: Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. Article Snippet: Background and Objectives In first-line treatment of advanced renal cell carcinoma (aRCC), the KEYNOTE-426 study demonstrated a significant progression-free survival and overall survival for pembrolizumab plus axitinib in comparison with sunitinib.. The objective of the current study was to evaluate the cost effectiveness of pembrolizumab plus axitinib versus sunitinib for previously untreated patients with aRCC in China.. Methods A Markov model was used to estimate the costs and health outcomes of treatment of aRCC with sunitinib or pembrolizumab plus axitinib. Article Title: Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma Article Snippet: .. The GetData Extraction:Article Title: Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma Article Snippet: .. The GetData |